IP Library Granted Patent US 11,078,298
Granted Patent B2
US 11,078,298 · App. 16/345,562 · Granted Aug 3, 2021

Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods

Inventors: Michael Catania (San Diego, CA); Ronald L. Hayes (San Diego, CA)
Assignee: BANYAN BIOMARKERS, INC.
C07K16/40A61B5/0042A61B5/055A61B6/032A61B6/501A61P25/00C07K16/18G01N33/6896C07K2317/20C07K2317/21C07K2317/34C07K2317/52C07K2317/565C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,078,298
App. No.
16/345,562
Granted
Aug 3, 2021
Kind
B2
Abstract

The invention provides anti-UCH-L1 antibodies and anti-GFAP antibodies and their use in vitro detection of UCH-L1 and GFAP, respectively, in a sample from an individual, such as an individual known or suspected of having a brain injury or damage, for example, neurological damage such as mild traumatic brain injury. Also provided are methods, systems and kits for diagnosing brain injury or damage, such as neurological damage, in an individual with the aforementioned antibodies as well as compositions comprising the anti-UCH-L1 antibodies and anti-GFAP antibodies.

Claims (4)

1. An antibody or antigen-binding fragment thereof that specifically binds to a human ubiquitin c-terminal hydrolase L I (UCH-L 1), wherein the antibody or antigen-binding fragment comprises a heavy chain variable region and a light chain variable region, wherein:

the heavy chain variable region comprises: (i) a CDR-HL comprising the amino acid sequence of SEQ ID NO:1; (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO:9; and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO:20; and

wherein the light chain variable region comprises: (i) a CDR-LI comprising the amino acid sequence of SEQ ID NO:28; (ii) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:37; and (iii) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:45.

2. A composition comprising the antibody or antigen-binding fragment of claim 1 .

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2026
From: BANYAN BIOMARKERS, INC.
To: BIOMERIEUX, INC.
Reel/Frame 074323/0554 →
CHANGE OF ADDRESS OF ASSIGNEE Recorded Nov 12, 2024
From: BANYAN BIOMARKERS, INC.
To: BANYAN BIOMARKERS, INC.
Reel/Frame 069340/0120 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 10, 2019
From: CATANIA, MICHAEL; HAYES, RONALD L.
To: BANYAN BIOMARKERS, INC.
Reel/Frame 050329/0248 →
Continuity (2)
Provisional Application 62414569 · Oct 28, 2016
Related Publication 20200165355A1 · May 28, 2020
Cited By (1)
US 12,601,749